Despite recommendations, statin use ‘not ubiquitous’ in CKD with ASCVD

Overall statin use among adults with chronic kidney disease is high, yet there have been only modest increases in the use of high‐intensity statins, ezetimibe and PCSK9 inhibitors, data from a prospective 2‐year study show.

Both the 2013 Kidney Disease: Improving Global Outcomes (KDIGO) and 2018 American College of Cardiology/American Heart Association cholesterol guidelines recommend at least statin therapy for adults with non‐dialysis-dependent chronic kidney disease (CKD) and atherosclerotic CVD, as CKD is a major risk factor for disease progression, Robert S. Rosenson, MD, director of metabolism and lipids for the Mount Sinai Health System and professor of medicine in cardiology at the Icahn School of Medicine at Mount Sinai, and colleagues wrote. Read the full story in Healio.